Cargando…

RNA modification in cardiovascular disease: implications for therapeutic interventions

Cardiovascular disease (CVD) is the leading cause of death in the world, with a high incidence and a youth-oriented tendency. RNA modification is ubiquitous and indispensable in cell, maintaining cell homeostasis and function by dynamically regulating gene expression. Accumulating evidence has revea...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Cong, Hou, Xuyang, Guan, Qing, Zhou, Huiling, Zhou, Li, Liu, Lijun, Liu, Jijia, Li, Feng, Li, Wei, Liu, Haidan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603151/
https://www.ncbi.nlm.nih.gov/pubmed/37884527
http://dx.doi.org/10.1038/s41392-023-01638-7
_version_ 1785126543281881088
author Wang, Cong
Hou, Xuyang
Guan, Qing
Zhou, Huiling
Zhou, Li
Liu, Lijun
Liu, Jijia
Li, Feng
Li, Wei
Liu, Haidan
author_facet Wang, Cong
Hou, Xuyang
Guan, Qing
Zhou, Huiling
Zhou, Li
Liu, Lijun
Liu, Jijia
Li, Feng
Li, Wei
Liu, Haidan
author_sort Wang, Cong
collection PubMed
description Cardiovascular disease (CVD) is the leading cause of death in the world, with a high incidence and a youth-oriented tendency. RNA modification is ubiquitous and indispensable in cell, maintaining cell homeostasis and function by dynamically regulating gene expression. Accumulating evidence has revealed the role of aberrant gene expression in CVD caused by dysregulated RNA modification. In this review, we focus on nine common RNA modifications: N(6)-methyladenosine (m(6)A), N(1)-methyladenosine (m(1)A), 5-methylcytosine (m(5)C), N(7)-methylguanosine (m(7)G), N(4)-acetylcytosine (ac(4)C), pseudouridine (Ψ), uridylation, adenosine-to-inosine (A-to-I) RNA editing, and modifications of U34 on tRNA wobble. We summarize the key regulators of RNA modification and their effects on gene expression, such as RNA splicing, maturation, transport, stability, and translation. Then, based on the classification of CVD, the mechanisms by which the disease occurs and progresses through RNA modifications are discussed. Potential therapeutic strategies, such as gene therapy, are reviewed based on these mechanisms. Herein, some of the CVD (such as stroke and peripheral vascular disease) are not included due to the limited availability of literature. Finally, the prospective applications and challenges of RNA modification in CVD are discussed for the purpose of facilitating clinical translation. Moreover, we look forward to more studies exploring the mechanisms and roles of RNA modification in CVD in the future, as there are substantial uncultivated areas to be explored.
format Online
Article
Text
id pubmed-10603151
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-106031512023-10-28 RNA modification in cardiovascular disease: implications for therapeutic interventions Wang, Cong Hou, Xuyang Guan, Qing Zhou, Huiling Zhou, Li Liu, Lijun Liu, Jijia Li, Feng Li, Wei Liu, Haidan Signal Transduct Target Ther Review Article Cardiovascular disease (CVD) is the leading cause of death in the world, with a high incidence and a youth-oriented tendency. RNA modification is ubiquitous and indispensable in cell, maintaining cell homeostasis and function by dynamically regulating gene expression. Accumulating evidence has revealed the role of aberrant gene expression in CVD caused by dysregulated RNA modification. In this review, we focus on nine common RNA modifications: N(6)-methyladenosine (m(6)A), N(1)-methyladenosine (m(1)A), 5-methylcytosine (m(5)C), N(7)-methylguanosine (m(7)G), N(4)-acetylcytosine (ac(4)C), pseudouridine (Ψ), uridylation, adenosine-to-inosine (A-to-I) RNA editing, and modifications of U34 on tRNA wobble. We summarize the key regulators of RNA modification and their effects on gene expression, such as RNA splicing, maturation, transport, stability, and translation. Then, based on the classification of CVD, the mechanisms by which the disease occurs and progresses through RNA modifications are discussed. Potential therapeutic strategies, such as gene therapy, are reviewed based on these mechanisms. Herein, some of the CVD (such as stroke and peripheral vascular disease) are not included due to the limited availability of literature. Finally, the prospective applications and challenges of RNA modification in CVD are discussed for the purpose of facilitating clinical translation. Moreover, we look forward to more studies exploring the mechanisms and roles of RNA modification in CVD in the future, as there are substantial uncultivated areas to be explored. Nature Publishing Group UK 2023-10-27 /pmc/articles/PMC10603151/ /pubmed/37884527 http://dx.doi.org/10.1038/s41392-023-01638-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Wang, Cong
Hou, Xuyang
Guan, Qing
Zhou, Huiling
Zhou, Li
Liu, Lijun
Liu, Jijia
Li, Feng
Li, Wei
Liu, Haidan
RNA modification in cardiovascular disease: implications for therapeutic interventions
title RNA modification in cardiovascular disease: implications for therapeutic interventions
title_full RNA modification in cardiovascular disease: implications for therapeutic interventions
title_fullStr RNA modification in cardiovascular disease: implications for therapeutic interventions
title_full_unstemmed RNA modification in cardiovascular disease: implications for therapeutic interventions
title_short RNA modification in cardiovascular disease: implications for therapeutic interventions
title_sort rna modification in cardiovascular disease: implications for therapeutic interventions
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10603151/
https://www.ncbi.nlm.nih.gov/pubmed/37884527
http://dx.doi.org/10.1038/s41392-023-01638-7
work_keys_str_mv AT wangcong rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions
AT houxuyang rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions
AT guanqing rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions
AT zhouhuiling rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions
AT zhouli rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions
AT liulijun rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions
AT liujijia rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions
AT lifeng rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions
AT liwei rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions
AT liuhaidan rnamodificationincardiovasculardiseaseimplicationsfortherapeuticinterventions